ArticleCommunications biology2025
Genomic characterization of host gene alterations in Theileria annulata-transformed leukocytes.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Theileria annulata-infected host leukocytes exhibit cancer-like phenotypes, driven by mechanisms that remain incompletely understood. This study explores the genomic alterations underlying these transformations using whole-genome sequencing and bioinformatic analyses of six clinically relevant T. annulata-infected cell lines. Here we identify 7867 exon-linked somatic mutations shared across all cell lines, with significant enrichment in oncogenes (e.g., FLT4, NOTCH2, MAP3K1, DAXX, FCGR2B, ROS1) and tumor suppressor genes (e.g., BARD1, KMT2C, GRIN2A, BAP1). These mutations are associated with critical cancer-related pathways. Functional studies revealed that inhibition of the mutated oncogene ROS1 using crizotinib induces death in infected leukocytes, confirming its role in transformation. Additionally, we observe mutations in genes linked to genomic instability and the DNA damage response (DDR) pathways, highlighting potential parallels with cancer biology. Suppression of TP53, a key tumor suppressor, is implicated in the immortalization of infected cells, while upregulation of the DNA mutator enzyme APOBEC3H suggests a parasite-driven, mutation-inducing mechanism. Our findings provide new insights into how T. annulata reprograms host cells through genomic instability and mutations, identifying ROS1 and TP53 as critical targets for therapeutic intervention. This work advances understanding of parasite-induced oncogenic transformation and offers pathways for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.